iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
May 18, 2023
Company presented portfolio of breast cancer
detection, density assessment and risk evaluation solutions at the competition,
focused on improving health outcomes
NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its Breast AI Suite is a winner of the U.S. General Services
Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio
of breast cancer detection, density assessment and risk evaluation solutions at
the competiti... Continue reading
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
May 15, 2023
Company to host conference call and webcast today at
4:30 PM ET
NASHUA,
N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
reported its financial and operating results for the three months ended March
31, 2023.
Highlights:
Body of evidence supporting iCAD’s technologies grows, with compelling new research supporting Company’s Breast AI Suite and...
Continue reading
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
May 11, 2023
98.9% of patients treated with Xoft remained
recurrence-free at a median follow-up of 7.6 years, according to recent study published
in Journal of Contemporary Brachytherapy
NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced compelling new long-term real-world research confirms Xoft Skin eBx
is as safe and effective as Mohs surgery for the treatment of non-melanoma skin
cancer (NMSC). In the longest-term study of Xof... Continue reading
iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference
May 03, 2023
iCAD’s AI solution minimizes interval cancers and
overcomes challenges associated with digital breast tomosynthesis
NASHUA, N.H., May 3, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced it will showcase its Breast AI Suite of cancer detection, density
assessment and risk evaluation solutions at the world’s largest breast imaging
conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7
in National Harbor, MD. Attendees are i... Continue reading
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023
NASHUA, N.H., May 1, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a
global medical technology leader providing innovative cancer detection and
therapy solutions, today announced that it will release financial results for
the first quarter ended March 31, 2023, after the market close, and host a
conference call at 4:30 PM Eastern Time on Monday, May 15, 2023.
Earnings call details are as follows:
Domestic: 877-545-0523
International: 973-528-0016
Continue reading
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
April 25, 2023
Kathy Schilling, MD, Boca Raton Regional Hospital, to
discuss how ProFound AI helped nine dedicated breast radiologists find 23% more
cancers, without increasing the rate of recalls
NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy
Schilling, MD, Medical Director, Christine E. Lynn Women's Health &
Wellness Institute, Boca Raton Regional Hospital. The live event,... Continue reading
New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection and Reveals Critical Clues to Inform Clinical Decisions
April 20, 2023
New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients
NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced new real-world research confirms ProFound AI® has been proven to
increase cancer detection rates and provide vital clues for breast imagers'
clinical decisions through two studies. One... Continue reading
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
April 17, 2023
Eric Lonnqvist as Chief Financial Officer, Vasu
Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations
Officer bolster the Company’s executive leadership team and accelerate the
Company’s growth strategies
NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced the Board of Directors has approved the appointment of Eric Lonnqvist
as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula
as Chief Pro... Continue reading
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
April 04, 2023
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick
v8 for all women, regardless of menopausal status, breast density, and family
history of breast cancer
NASHUA, N.H., April 4, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced new clinical evidence published in the Journalof Clinical Oncology found ProFound AI® Risk for 2D Mammography
is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model,
for both short-term... Continue reading
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
March 28, 2023
Strategy focused on profitability by end of 2024,
using current cash on hand
New leadership to host conference call and webcast
today at 4:30 PM ET
NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today reported its financial and operating
results for the twelve months ended
December 31, 2022.
Highlig... Continue reading
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
March 23, 2023
iCAD showcases Breast AI Suite at National Consortium
of Breast Centers (NCoBC) 32nd Annual Conference
NASHUA, N.H., March 23, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its technologies are empowering customers to lead the way in breast
care, while supporting the national breast density reporting standard recently established
by the U.S. Food and Drug Administration (FDA). The Company will be showcasing
its Breast AI Suite... Continue reading
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
March 13, 2023
Company is exploring strategic options for its Therapy
business line
NASHUA, N.H., March 13, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced that it will release financial results for the fourth quarter
and year ended December 31, 2022, after the market close, and host a conference
call at 4:30 PM ET on Tuesday, March 28, 2023.
Based on preliminary, unaudited
financial infor... Continue reading
iCAD Announces Leadership Transition
March 13, 2023
Stacey
Stevens Resigns as President and CEO and as a Member of the Board
Dana
Brown Named President and CEO, remains Chairman of the Board
NASHUA, N.H. – March 13, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced the Board of Directors has accepted the resignation, for
personal reasons, of Stacey Stevens as President and CEO. Stacey will remain
with the Company through Apr... Continue reading
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy
March 01, 2023
Company’s Breast AI Suite of deep-learning breast
cancer detection, density assessment and risk evaluation tools showcased at ECR
2023
NASHUA, N.H. – March 1, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced new real-world clinical evidence to be presented at the
European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts
radiologists’ efficiency and accuracy. The Company is also showcasing its
Breast AI Suite of deep... Continue reading
iCAD to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 09, 2023
NASHUA, N.H., February 9, 2023 -- iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer detection
and therapy solutions, today announced the Company will participate in the BTIG
Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools
Conference from February 14-16, 2023 in Snowbird, UT.
Stacey Stevens, President and CEO of iCAD, Inc., will participate
in one-on-one meetings with investors at the event. Please contact your BTIG
representative for further information or to request a meeting.
Continue reading
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
January 23, 2023
Daniel
Shea appointed as interim Chief Financial Officer
William
Keyes hired as Senior Vice President, US Commercial Sales, AI
NASHUA, N.H. – January 23, 2023 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today
announced the
Board of Directors has approved the appointment of Daniel Shea, CPA, as interim
Chief Financial Officer (CFO), effective immediately. The Company has launched
a search for a full-time CFO, with the goal... Continue reading
iCAD Announces Board of Directors Transition
January 11, 2023
Dana
Brown named Executive Chair of the Board
NASHUA,
N.H. – January 11, 2023 - iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced the appointment of Dana Brown as Executive Chair of the Board
of Directors. Ms. Brown has been a non-executive board member since February
2022. Prior to joining iCAD’s board, Ms. Brown was the Senior Vice President,
Chief Strategy and Operations Officer for... Continue reading
iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar
December 08, 2022
Solis
Mammography’s Chief Medical Officer Chirag Parghi, MD, to share clinical
experience and real-world case studies demonstrating clinical value of ProFound
AI
NASHUA, N.H. – December 5, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Solis Mammography, the largest independent provider of breast screening and diagnostic services in the United States, will be featured in the next “ProFound Insights, ProFound Impact” webinar, on Dec. 14 at 3 pm EST / 12 pm P... Continue reading
iCAD and Google Health Ink Strategic Development and Commercialization Agreement
November 28, 2022
Google Health AI and
Cloud technology to be integrated into iCAD’s portfolio with potential to
elevate performance and expand access to millions of women worldwide
Agreement marks Google
Health’s first partnership with a mammography AI vendor
NASHUA, N.H. – November 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced a
strategic development... Continue reading
Positive New Research Presented at RSNA 2022 Reaffirms iCAD’s Breast AI Suite Improves Radiologists’ Performance and Breast Cancer Detection
November 21, 2022
Study affirms
utility of ProFound AI’s Case Scores in improving cancer detection
Company’s Breast AI Suite of deep-learning breast
cancer detection, density assessment and risk evaluation tools showcased at largest
medical imaging forum in the world
NASHUA, N.H. – November 21, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced new and real-world research demonstrating the value
of its Breast AI Suit... Continue reading
100 Comments